Rhenman & Partners strengthens its Investor Relations team further

Rhenman & Partners hires Mattias Hagen as Investor Relations Director. Mattias joins Rhenman & Partners Investor Relations team based in Stockholm consisting of Erica von Bahr and Tom Josephson. In his role, Mattias will work both with Swedish and international investors. Most recently Mattias has worked with institutional investors at Carnegie Fonder. Prior to that he worked in distribution roles at Invesco and Goldman Sachs. He started his career at Skandia and later moved on to SEB Wealth Management, where he spent 10 years in various roles, including Head of Manager Research.

“It is very exciting and inspiring to join Rhenman & Partners. I see them as one of the Nordic region’s strongest niche asset managers. I look forward to being a part of the continued development of the firm.” – says Mattias Hagen

“We are very pleased that Mattias is joining Rhenman & Partners. His broad skill set and experience make him a strong addition to our organization. Mattias will be an important part of our contacts with investors, both in Sweden and internationally.” – says Teresa Isele, CEO of Rhenman & Partners

Mattias is one of several recruitments Rhenman & Partners has made over the past months. Earlier this year, Tom Josephson joined the firm’s Investor Relations team, and in September Camilla Oxhamre Cruse joined the investment team as a Biopharma Portfolio Manager.

Mattias starts his position with Rhenman & Partners in October and will be based in their Stockholm office.

Mattias Hagen

Click here for a PDF version of the news article.

For more information, please contact:

Karin Hjertén | Head of Communications, Rhenman & Partners Asset Management

E-post: karin@rhepa.com | Telephone: +46 (0)706521908

Om Rhenman & Partners Asset Management

Rhenman & Partners Asset Management AB (Rhepa) was founded in 2008 and is a Stockholm-based asset manager with a sole focus on the healthcare sector. Rhepa is responsible for the portfolio of a sector fund registered in Luxembourg. The fund is managed by FundRock Management Company S.A. who has commissioned Rhepa to manage the fund’s portfolio. Rhepa’s experienced investment team is supported by a scientific advisory board consisting of medical experts with a global network of researchers and specialists.

This is marketing material, the material is for informational purposes only and should not be considered as an offer or solicitation to sell or buy shares in the fund. Read the AIF fund’s prospectus as well as the KIID (which can be ordered free of charge or downloaded at www.rhepa.com) before making any definitive investment decisions. Historical returns are no guarantee of future returns. Investments involve a risk. The money invested in the fund can both increase and decrease in value and it is not certain that investors will get back all the invested capital. FundRock Management Company S.A., Luxembourg has commissioned Rhenman & Partners Asset Management AB to manage the portfolio in a Luxembourg-registered sector fund. Rhenman & Partners is not authorized to give – and will not give – investment advice to investors. Investors and potential investors considering investing in the Fund should discuss this with a professional investment adviser.